brimonidine ophthalmic
Selected indexed studies
- Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy. (Expert Rev Clin Pharmacol, 2022) [PMID:35951740]
- Brimonidine. (Profiles Drug Subst Excip Relat Methodol, 2023) [PMID:37061271]
- A review of neuropsychiatric adverse events from topical ophthalmic brimonidine. (Hum Exp Toxicol, 2020) [PMID:32347114]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy. (2022) pubmed
- Brimonidine. (2023) pubmed
- A review of neuropsychiatric adverse events from topical ophthalmic brimonidine. (2020) pubmed
- Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension. (2006) pubmed
- Inflammatory Cells and Lipid Deposits Detected by in Vivo Confocal Microscopy in Brimonidine Tartrate Ophthalmic Solution-Related Corneal Disorders: A Case Series. (2023) pubmed
- Effects of Brimonidine, Omidenepag Isopropyl, and Ripasudil Ophthalmic Solutions to Protect against H(2)O(2)-Induced Oxidative Stress in Human Trabecular Meshwork Cells. (2023) pubmed
- Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial. (2018) pubmed
- Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study. (2022) pubmed
- The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations. (2020) pubmed
- Clinical effects of brimonidine ophthalmic drops ingestion in 52 dogs. (2002) pubmed